Genetic testing company Natera (NASDAQ:NTRA). will be announcing earnings results tomorrow after market close. Here’s what to ...

Natera Inc (NASDAQ:NTRA) is set to release its Q4 2024 earnings on Feb 27, 2025. The consensus estimate for Q4 2024 revenue ...

Delaware federal judge reverses jury verdict in CareDx’s favour | Natera’s patents covering organ transplant testing ...

The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high- ...

The test has met coverage requirements for use with patients with non-small cell lung cancer with resectable or unresectable disease in the surveillance setting.

Columbia Select Large Cap Equity Fund Institutional Class shares returned 3.31% for the three months ending 12/31/2024. Click ...

CareDx (CDNA) announced that the District Court overturned the jury verdict in patent litigation brought by a competitor. The District Court ...

Natera (NTRA) announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services’ Molecular ...

Natera, Inc. , a global leader in cell-free DNA and genetic testing, today announced that its Signatera test has met coverage requirements from the Centers for Medicare & Medicaid Services' (CMS) ...

Natera (NASDAQ:NTRA – Get Free Report) is anticipated to issue its quarterly earnings data after the market closes on Thursday, February 27th. Analysts expect the company to announce earnings of ...

A federal judge on Monday threw out a $96 million jury verdict against genetic testing company CareDX that rival Natera had ...

Columbia Large Cap Growth Fund Institutional Share Class Shares returned 5.71% for Q4 2024. Click here to read the full ...